Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.0K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.0K
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

1.0K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.0K
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

424
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
424
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

1.6K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.6K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

1.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stability of Type 2 Inflammation in a 12-Year Adult-Onset Asthma Follow-Up Study.

Journal of asthma and allergy·2026
Same author

Transient receptor potential ankyrin 1 promotes the expression of interferon-stimulated antiviral genes in human A549 lung epithelial cells.

Molecular pharmacology·2026
Same author

Repeated Intake of Grapefruit Juice Inhibits CYP2B6, CYP2C9, CYP2C19, and CYP3A4 while Lingonberry Powder Does Not Induce Major CYP Enzymes in Humans.

Clinical pharmacology and therapeutics·2025
Same author

Immunometabolic profiling in menopausal women with multiple sclerosis: the role of adipokines and hormone therapy.

BMJ neurology open·2025
Same author

Dexamethasone regulates gene expression in chondrocytes through MKP-1 and downregulates cholesterol hydroxylases CH25H and CYP7B1.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2025
Same author

Antiosteolytic Bisphosphonate Metallodrug Coordination Networks: Dissolution Profiles and <i>In Vitro/In Vivo</i> Toxicity toward Controlled Release.

ACS applied bio materials·2025

Related Experiment Video

Updated: Jun 17, 2025

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3
07:26

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3

Published on: August 17, 2011

21.1K

TRPA1 Inhibition Effects by 3-Phenylcoumarin Derivatives.

Carita Sallomy1, Paul Awolade2, Minna Rahnasto-Rilla1

  • 1School of Pharmacy, University of Eastern Finland, Kuopio 70211, Finland.

ACS Medicinal Chemistry Letters
|August 14, 2024
PubMed
Summary

Researchers identified novel 3-phenylcoumarin compounds as inhibitors of the Transient Receptor Potential Ankyrin 1 (TRPA1) protein. These compounds show potential for treating pain and inflammation, with one also impacting breast cancer cells.

More Related Videos

Planarian Scrunching as a Quantitative Behavioral Readout for Noxious Stimuli Sensing
10:15

Planarian Scrunching as a Quantitative Behavioral Readout for Noxious Stimuli Sensing

Published on: July 30, 2020

6.9K
Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
08:39

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents

Published on: May 16, 2022

2.3K

Related Experiment Videos

Last Updated: Jun 17, 2025

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3
07:26

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3

Published on: August 17, 2011

21.1K
Planarian Scrunching as a Quantitative Behavioral Readout for Noxious Stimuli Sensing
10:15

Planarian Scrunching as a Quantitative Behavioral Readout for Noxious Stimuli Sensing

Published on: July 30, 2020

6.9K
Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
08:39

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents

Published on: May 16, 2022

2.3K

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Computational Drug Design

Background:

  • Transient Receptor Potential Ankyrin 1 (TRPA1) is implicated in inflammatory responses and pain conditions.
  • TRPA1 presents a viable target for developing novel analgesic and anti-inflammatory drugs.

Purpose of the Study:

  • To identify and design potential TRPA1 inhibitors using computer-aided drug design (CADD).
  • To synthesize and evaluate the inhibitory activity of novel 3-phenylcoumarin derivatives against TRPA1.
  • To explore the potential therapeutic applications of these compounds in pain, inflammation, and cancer.

Main Methods:

  • Utilized computer-aided drug design (CADD) to identify potential TRPA1 binding sites and inhibitors.
  • Employed microwave-assisted synthesis to create a library of 3-phenylcoumarin derivatives.
  • Conducted in vitro assays to assess the TRPA1 inhibitory activity of synthesized compounds.

Main Results:

  • Successfully synthesized several 3-phenylcoumarin-based compounds with TRPA1 inhibitory activity.
  • Compounds 3-(3-Bromophenyl)-7-acetoxycoumarin (5), 7-hydroxy-3-(3-hydroxyphenyl)coumarin (12), and 3-(3-hydroxyphenyl)coumarin (23) demonstrated significant TRPA1 inhibition in vitro.
  • Compound 5 exhibited additional activity by reducing breast cancer cell size and formation.

Conclusions:

  • Targeting TRPA1 with novel 3-phenylcoumarin derivatives offers a promising therapeutic strategy for pain and inflammation.
  • The identified compounds warrant further investigation for their potential in treating TRPA1-associated diseases, including cancer.